ER-Positive Breast Cancer

Biosimilar Promising for Treatment of ERBB2+ Breast Cancer

Biosimilar Promising for Treatment of ERBB2+ Breast Cancer

Equivalent response rate for women with ERBB2-positive metastatic breast cancer receiving taxanes

Preventative therapies for healthy women at high risk of breast cancer

Preventative therapies for healthy women at high risk of breast cancer

SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting for ER-positive breast cancer, but newer agents must be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.

Drug resistance reversed when tamoxifen is paired with antimalarial agent

By

The antimalarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen in mice, according to investigators.

Treating breast cancer drug resistance via a malaria drug

Treating breast cancer drug resistance via a malaria drug

An inexpensive malaria drug could be the answer for some women who are not responding to their cancer treatment, according to a promising but preliminary animal study.

ASCO: Obesity and ER+ breast cancer mortality link limited to pre-menopause

ASCO: Obesity and ER+ breast cancer mortality link limited to pre-menopause

In estrogen receptor (ER)+ breast cancer, obesity is positively associated with breast cancer mortality only among pre-/peri-menopausal women, according to new research.

Smoking increases ER-positive breast cancer risk for women

Smoking increases ER-positive breast cancer risk for women

Younger women who smoke appear to be at increased risk for developing ER-positive breast cancer, according to research, but no association found for risk of triple-negative breast cancer.

Models of drug-resistant breast cancer suggest better treatments

By

Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research presented at the 2013 San Antonio Breast Cancer Symposium.

Endoxifen promising as treatment for ER-positive breast cancer

By

A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.

New driver of breast cancer discovered

By

As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.

Resistance to breast cancer treatment tied to mutations in estrogen receptor

Resistance to breast cancer treatment tied to mutations in estrogen receptor

By

A type of mutation that develops after breast cancer patients take antiestrogen therapies has been identified. These mutations help to explain why patients often become resistant to these types of therapies.

Biomarker based on gene expression predicts long-term risk for breast cancer recurrence

By

The breast cancer index (BCI) was the only one of three methods compared that predicted the risk for recurrence in women treated for estrogen-receptor (ER)-positive breast cancer.

New hope for estrogen-resistant breast cancer

By

A specific change that occurs when breast cancer tumors become resistant to antiestrogen therapy might make the tumors susceptible to treatment with chemotherapy drugs.

New drug target and companion prognostic test for hormone therapy-resistant breast cancer

By

Researchers have identified the signaling pathway that is overactivated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors, or fulvestrant.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs